![newborn_infant_christian_bowen_unsplash](https://pharmaphorum.com/wp-content/uploads/2022/09/newborn_infant_christian_bowen_unsplash.jpg)
CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevent...
Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.<